Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
The purpose of this study is to show that the use of low volume iso-osmolar non-ionic radio contrast medium (30 cc) in a thoracic CT Scanning procedure in a selected group of patients with chronic kidney disease (CKD) will avoid contrast induced nephropathy (CIN) in comparison to a similar group of patients with CKD who receive no contrast medium..
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 28, 2017 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- VA Greater Los Angeles Healthcare System
- Interventions being studied
- Drug: Low Volume iso-osmolar non-ionic radio contrast medium; Drug: Acetylcysteine Inhalation; Drug: Sodium Bicarbonate Solution; Procedure: 64-MDCT Scanning
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Subjects with documented stable Chronic Kidney Disease (CKD) defined as a stable eGFR 16-60 ml/min/m\^2 for ≥ 12 months; and
- Referred to CT scanning procedure to evaluate pulmonary embolism, pulmonary malignancy, acute aortic syndromes, or renal artery stenosis.
- CKD Stages 1, 2 and 5
- Stage 3-4 congestive heart failure (CHF)
- Irregular supraventricular tachycardia
- Allergic to iodinated Radio Contrast Medium (RCM)
- Allergic to Mucomyst
- Pregnancy
- Evidence of acute renal failure (ARF)
- Serum bicarbonate either less than 20 meq/L or greater than 35 meq/L
- Hydration with a bicarbonate solution is contraindicated or considered unsafe by the subject's caring physicians
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- VA Greater Los Angeles Healthcare SystemLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 28, 2017. Always confirm current availability with the study team.